I asked Sarah about the upcoming EAS and ATVB conference presentations and she replied 

"Yes, we are presenting at both conferences.

 EAS-

 1)     Poster- Apabetalone (RVX-208) May Lower CVD Events in Diabetes Mellitus by Affecting Complement Pathway and Microbiome Activity

ATVB-

1)     Poster- Apabetalone (RVX-208), A Selective Bet Protein Inhibitor, Reduces Expression Of Acute Phase Response Markers In Vitro And In Patients With Cardiovascular Disease And Chronic Kidney Disease

2)     Oral Presentation- Selective BET inhibitors are useful for normalizing inflammation leading to reduced cardiovascular disease (CVD) in humans"